Targeting XPO1 offers a promising therapeutic strategy by retaining multiple tumor suppressor proteins in the nucleus, preventing the translation of oncoproteins, inducing transient cell-cycle arrest, suppressing tumor growth, and promoting apoptosis. The gene discussed is XPO1; the disease is neoplasm.